Stockreport

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial [Yahoo! Finance]

Protagenic Therapeutics, Inc.  (PTIX) 
US:NASDAQ Investor Relations: protagenic.com/investors
PDF the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric di [Read more]